Targets › MAP2K2
15 programs from 14 companies in 229 trials: 117 Phase 2, 66 Phase 1, 25 Phase 4, 21 Phase 3; Oncology, Other, Cardiovascular; next expected readout Nov 2026.
Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity). (UniProt, P36507)
Open in Phaseline: the race on MAP2K2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Trametinib Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor | MAP2K2, MAP2K1 | Phase 4 | Diffuse Astrocytoma; Melanoma; Differentiated Thyroid Cancer (DTC); EGFR-mutant Non-small Cell Lung Cancer … | Nov 2026 |
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| Pfizer | Binimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 4 | Solid Tumors; Melanoma | Jul 2029 |
| Pierre Fabre Medicament | Binimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Melanoma; Non-Small Cell Lung Cancer; Solid Tumor, Adult; Solid Tumor … | Dec 2026 |
| Verastem | avutometinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Low Grade Serous Ovarian Cancer; Low Grade Ovarian Serous Adenocarcinoma; Non Small Cell Lung Cancer; KRAS Activating Mutation … | Dec 2026 |
| Shanghai Kechow Pharma | tunlametinib MEK1/2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Colorectal Cancer Metastatic; Melanoma; Melanoma Advanced; Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation … | Dec 2026 |
| AstraZeneca | Selumetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV; Neurofibromatosis 1; Advanced Non Small Cell Lung Cancer; Tumor … | Dec 2026 |
| Chia Tai Tianqing Pharmaceutical Group | TQ-B3234 capsules Selective MEK1/2 inhibitor | MAP2K1, MAP2K2 | Phase 3 | Plexiform Neurofibroma | Dec 2027 |
| Roche | Cobimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 2 | Non-small Cell Lung Cancer; Melanoma; Metastatic Distal Bile Duct Adenocarcinoma; Chronic Myelomonocytic Leukemia (CMML) … | Nov 2026 |
| Roche | Cobimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 2 | Non-Small Cell Lung Cancer; Ovarian Cancer | Jun 2027 |
| SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Mirdametinib (PD-0325901) Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 2 | Plexiform Neurofibroma; Healthy; Slow-Flow Vascular Malformation; Advanced Unresectable Melanoma … | Dec 2028 |
| Hanmi Pharmaceutical Company | Cobimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 2 | Advanced or Metastatic Melanoma | Sep 2029 |
| Merck KGaA | Mirdametinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 1 | Healthy | Nov 2026 |
| Recursion Pharmaceuticals | Tak-733 (REC-4881) Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 1 | Familial Adenomatous Polyposis | Jun 2027 |
| Pasithea Therapeutics | PAS-004 MEK 1/2 inhibitor | MAP2K1, MAP2K2 | Phase 1 | RAS Mutation; NF1 Mutation | Sep 2027 |
Melanoma (8) Advanced Lymphoma (6) Neurofibromatosis 1 (5) Neurofibromatosis Type 1 (3) Low Grade Glioma (3) Non-small Cell Lung Cancer (3) Non-Small Cell Lung Cancer (3) Metastatic Malignant Neoplasm in the Brain (3) Nicotine Dependence (3) Metastatic Melanoma (2) Solid Tumor, Adult (2) Solid Tumor (2)
small molecule (12), mixed (3)
Roche (2) AstraZeneca (1) Pierre Fabre Medicament (1) Shanghai Kechow Pharma (1) Pasithea Therapeutics (1) Novartis (1) Merck KGaA (1) SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (1) University of California, San Francisco (1) Verastem (1) Pfizer (1) Chia Tai Tianqing Pharmaceutical Group (1) Recursion Pharmaceuticals (1) Hanmi Pharmaceutical Company (1)
MAP2K1 (15) ADRB2 (1) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) HTR2A (1) MS4A1 (1) CHRM3 (1) CHRM2 (1) ADRB3 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.